US EditionPublished • loading... • Updated
Real-World Evidence [RWE] Demonstrates Repatha’s Long-Term Cardiovascular Benefits
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Real-World Evidence [RWE] Demonstrates Repatha’s Long-Term Cardiovascular Benefits
RWE Supports Repatha’s Effectiveness in Reducing Major Adverse Cardiovascular Events (MACE) in Patients with ASCVD Data Presented at American Heart Association Scientific Sessions 2025 DURHAM, N.C.--(BUSINESS WIRE)--#ASCVD--Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced the presentation of compelling new findings from the REPATHA-CE study of more [...] The post Real-Wo…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
